WO2007101357A3 - Haarwuchsmittel zur behandlung von menschlichen keratinfasern und verfahren zu dessen herstellung - Google Patents

Haarwuchsmittel zur behandlung von menschlichen keratinfasern und verfahren zu dessen herstellung Download PDF

Info

Publication number
WO2007101357A3
WO2007101357A3 PCT/CH2007/000089 CH2007000089W WO2007101357A3 WO 2007101357 A3 WO2007101357 A3 WO 2007101357A3 CH 2007000089 W CH2007000089 W CH 2007000089W WO 2007101357 A3 WO2007101357 A3 WO 2007101357A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
butyl avocadate
pyrimidine oxide
treatment
production
Prior art date
Application number
PCT/CH2007/000089
Other languages
English (en)
French (fr)
Other versions
WO2007101357A2 (de
Inventor
Nazmi Krasniqi
Original Assignee
Pelloni Claudio
Nazmi Krasniqi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelloni Claudio, Nazmi Krasniqi filed Critical Pelloni Claudio
Publication of WO2007101357A2 publication Critical patent/WO2007101357A2/de
Publication of WO2007101357A3 publication Critical patent/WO2007101357A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Das Mittel enthält Butyl-Avocadate und ist als Haarwuchsmittel zur lokalen Behandlung von Alopecia androgenetica geeignet. Das Butyl-Avocadate wird bevorzugt mit mindestens einem Pyrimidin Oxid oder Pyrimidin Oxid Derivat, zum Beispiel ein 2,4-Diaminopyrimidin 3-Oxid Derivat, und mit mindestens einem Bioflavanoid und/oder mit Dimethylsulfoxid kombiniert. Vorteilhaft ist das Butyl-Avocadate in einer Konzentration von 5 - 50 % vorhanden. Als Pyrimidin Oxid Derivate kommen insbesondere Minoxidil, Kopexil und/oder Kopyrrol in Frage. Als Bioflavanoide beispielsweise Taxifolin, Astibilin, Myricetin, Oligomere Procyanidin, Catechin, Epicate- chin, Ferulsäure und/oder Pycnogenol. Durch dieses Mittel kommt es nach relativ kurzer Zeit zu einem signifikanten Wachstum normaler Haare, das heisst, zu einem anagenen Wachstum. Dies besonders dann, wenn es neben dem Butyl-Avocadate gleichzeitig zwei Pyrimidin Oxid Derivate und mindestens ein Bioflavanoid oder Dimethylsulfoxid enthält. Das Mittel ist gut verträglich.
PCT/CH2007/000089 2006-03-07 2007-02-21 Haarwuchsmittel zur behandlung von menschlichen keratinfasern und verfahren zu dessen herstellung WO2007101357A2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH360/06 2006-03-07
CH3602006 2006-03-07
CH1340/06 2006-08-22
CH13402006 2006-08-22
CH203/07 2007-02-07
CH2032007 2007-02-07

Publications (2)

Publication Number Publication Date
WO2007101357A2 WO2007101357A2 (de) 2007-09-13
WO2007101357A3 true WO2007101357A3 (de) 2008-07-03

Family

ID=37951501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2007/000089 WO2007101357A2 (de) 2006-03-07 2007-02-21 Haarwuchsmittel zur behandlung von menschlichen keratinfasern und verfahren zu dessen herstellung

Country Status (1)

Country Link
WO (1) WO2007101357A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101497A2 (en) * 2008-02-11 2009-08-20 Glenmark Pharmaceuticals Limited Topical pharmaceutical combination comprising minoxidil and aminexil
CN101508782B (zh) * 2009-03-09 2013-01-16 东华大学 一种以有机酸溶剂分离提取天然角蛋白纤维中原纤状结构体的方法
WO2018229072A1 (de) * 2017-06-16 2018-12-20 Capilli Med Gmbh Zusammensetzung zur verhinderung von haarausfall und wachstumsförderung von haaren
CN107970128B (zh) * 2017-12-06 2021-01-15 彭氏(惠州)实业发展有限公司 一种含有二氨基嘧啶氧化物的生发液配方与生产工艺
CN114901247A (zh) * 2019-12-30 2022-08-12 莱雅公司 用于护理角蛋白材料的无水组合物
CN112370445A (zh) * 2020-10-13 2021-02-19 吉林大学 紫杉叶素在抑制毛发生长的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
WO1992001437A1 (fr) * 1990-07-20 1992-02-06 L'oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en ×uvre
WO2001052837A2 (fr) * 2000-01-18 2001-07-26 Laboratoires Pharmascience Utilisation d'au moins un ester gras pour la preparation d'une composition destinee a inhiber l'activite de la 5 alpha reductase, en pharmacie notamment en dermatologie, en cosmetique et en tant qu'additif alimentaire
EP1604640A1 (de) * 2004-04-30 2005-12-14 KPSS-Kao Professional Salon Services GmbH Mittel zur Behandlung der Haare und der Kopfhaut

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
WO1992001437A1 (fr) * 1990-07-20 1992-02-06 L'oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en ×uvre
WO2001052837A2 (fr) * 2000-01-18 2001-07-26 Laboratoires Pharmascience Utilisation d'au moins un ester gras pour la preparation d'une composition destinee a inhiber l'activite de la 5 alpha reductase, en pharmacie notamment en dermatologie, en cosmetique et en tant qu'additif alimentaire
EP1604640A1 (de) * 2004-04-30 2005-12-14 KPSS-Kao Professional Salon Services GmbH Mittel zur Behandlung der Haare und der Kopfhaut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PICCARDI ET AL.: "P02.14: Pharmacological and clinical activities of 5-alpha Avocuta. Application for the management of androgenic disorders", JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEROLOGY, vol. 18, no. s2, November 2004 (2004-11-01), pages 223 - 223, XP002465401 *

Also Published As

Publication number Publication date
WO2007101357A2 (de) 2007-09-13

Similar Documents

Publication Publication Date Title
WO2007101357A3 (de) Haarwuchsmittel zur behandlung von menschlichen keratinfasern und verfahren zu dessen herstellung
NZ590796A (en) Film-forming liquid formulations for drug release to hair and scalp
WO2009135006A3 (en) Methods for preventing oxidative damage to hair and promote hair shine
WO2006087392A3 (en) Substances, compositions and methods for treating alopecia
WO2007113851A3 (en) Novel compositions for hair disorders and process of preparation thereof
WO2009086457A3 (en) 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
WO2007002851A3 (en) Thermally-processed cocoa products useful for vascular health improvement
WO2009034559A3 (en) Cosmetic process for aesthetic and/or repairing treatment of the skin
WO2008139122A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2010013110A3 (en) Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness
TW200718430A (en) Cosmetic powder
WO2004043329A3 (en) Use of cellulose microbeads to make the skin matt
WO2007076006A3 (en) Skin protection and improvement
WO2001017486A3 (en) Deanol or derivatives for the treatment of skin impairements and baldness
WO2008139123A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2010132202A3 (en) Extended moisturization cosmetic compositions
BR0311568A (pt) Método de tratamento de cabelo e uso de uma composição
MX2009003060A (es) Emulsion.
WO2004073675A8 (de) Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
BRPI0917262A2 (pt) composto, composiçáo, método de tratamento ou prevenção de doença cardiovascular, método de fabricação de 3,4-metilenedioxifenil lipoato (inv-7065), método para tratamento de um indivíduo, suplemento dentário, composição anti-inflamatória, composição farmacêutica para tratamento de formação de placas aórticas humanas em um indivíduo, método para redução de formação de placas em um indivíduo, uso de um composto.
WO2009101497A3 (en) Topical pharmaceutical combination comprising minoxidil and aminexil
WO2008074578A3 (de) Mittel zum färben von keratinhaltigen fasern
WO2000048559A3 (en) Composition for promoting hair growth comprising derivatives of vitamins and dmso
WO2005004813A3 (en) Botanical extract compositions and process for preparing same
HK1127305A1 (en) Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07701889

Country of ref document: EP

Kind code of ref document: A2